Onconova Therapeutics Announces Plan for Expanding Rigosertib Clinical Trials for Patients with Myelodysplastic Syndromes (MDS) to South America with Pint Pharma

Pharmaceutical Investing

Onconova Therapeutics (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that its commercial partner, Pint Pharma GmbH, will assist in expanding access to clinical trials studying rigosertib, a novel and targeted anti-cancer compound currently in a Phase …

Onconova Therapeutics (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that its commercial partner, Pint Pharma GmbH, will assist in expanding access to clinical trials studying rigosertib, a novel and targeted anti-cancer compound currently in a Phase 3 study for the treatment of MDS, to several selected sites across South America.

As quoted in the press release:

“This assistance will help make rigosertib available to cancer patients on a fifth continent, following our ongoing clinical trials in North America, Europe, Asia and Australia. We are delighted to partner with Pint Pharma, which has a wide footprint in South and Central America, with first-hand experience in running clinical trials for malignant hematological disorders,” said Dr. Ramesh Kumar, CEO of Onconova Therapeutics, Inc.

“We are excited to start helping Onconova open new clinical sites in Latin America. We are hopeful that Onconova will be able to start recruiting patients as soon as possible to continue the development of IV and Oral Rigosertib,” said David Munoz, Chief Executive Officer of Pint Pharma. He added, “Rigosertib is highly complementary to our comprehensive hematology oncology portfolio, and will further strengthen our mission to enable the Latin American population with life-threatening conditions to live better lives by providing early and efficient access to innovative technologies.”

Click here to read the full press release.

The Conversation (0)
Ă—